loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Cipla Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Cipla Ltd. 30 Oct 2025 13:53 PM
Result PDF

Q2FY26 Quarterly Result Announced for Cipla Ltd.

Pharmaceuticals company Cipla announced Q2FY26 results

  • Income from Operations: Rs 7,589 crore compared to Rs 7,051 crore during Q2FY25, change 7.6%.
  • EBITDA: Rs 1,895 crore compared to Rs 1,886 crore during Q2FY25, change 0.5%.
  • EBITDA Margin: 25.0% for Q2FY26.
  • PAT: Rs 1,351 crore compared to Rs 1,303 crore during Q2FY25, change 3.7%.

Umang Vohra MD & Global CEO, Cipla, said: “I am pleased to share that we continue to make considerable progress across our focused markets. In Q2FY26, we delivered our highest-ever quarterly revenue of Rs 7,589 crore, with a robust EBITDA margin of 25%. What makes this performance commendable is the breadth and balance of our growth, driven by contributions across all our focused markets. Our One-India business grew at 7% YoY. Key therapies in Branded Prescription business continued to deliver strong market growth and with the launch of Yurpeak® (Tirzepatide), we mark a pivotal step into obesity care through our strategic partnership with Eli Lilly. Trade Generics recorded a double-digit growth and Anchor brands of Consumer Health Business maintained leadership position. With a positive traction in our differentiated assets, the US business posted a revenue of USD 233 million during the quarter. In Q3FY26, gRevlimid is expected to have a small contribution to the US revenue, with the base business expected to continue growing. Upcoming launches, subject to USFDA approvals, are expected to alleviate gRevlimid revenue decline over the next four quarters, though there may be a timing gap before the full benefit is realized. In One Africa, we achieved a healthy growth of 5% YoY in USD terms. Emerging Markets and Europe delivered a solid revenue growth of 15% YoY in USD terms on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front. “

Result PDF

Result PDF

Pharmaceuticals company Cipla announced Q1FY26 results

  • Income from Operations: Rs 6,957 crore compared to Rs 6,694 crore during Q1FY25, change 3.9%.
  • EBITDA: Rs 1,778 crore compared to Rs 1,716 crore during Q1FY25, change 3.6%.
  • EBITDA Margin: 25.6% for Q1FY26.
  • PAT: Rs 1,298 crore compared to Rs 1,178 crore during Q1FY25, change 10.2%.

Umang Vohra MD and Global CEO, Cipla, said: “I am pleased to share that we continue to make considerable progress across our focused markets. In Q3FY25, we delivered growth across all our various geographies, despite of a supply challenge in the U.S. We recorded a revenue growth of 8% over last year with a highest-ever EBITDA margin of 28.1%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 10% YoY. Key therapies in Branded Prescription business continued to outpace the market growth, Trade Generics business growth trajectory is back on track and Anchor brands of Consumer Health Business maintained leadership position. With a positive traction in our differentiated assets, the US business posted a revenue of $ 226 Mn. In South Africa, we recorded a solid growth of 21% YoY in local currency terms. Emerging Markets and Europe delivered a substantial revenue growth of 20% YoY on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front."

Result PDF

Pharmaceuticals company Cipla announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Income from Operations: Rs 6,730 crore compared to Rs 6,163 crore during Q4FY24, change 9.2%.
  • EBITDA: Rs 1,538 crore compared to Rs 1,316 crore during Q4FY24, change 16.8%.
  • EBITDA margin: 22.8% for Q4FY25.
  • PAT: Rs 1,222 crore compared to Rs 939 crore during Q4FY24, change 30.1%.

FY25 Financial Highlights:

  • Income from Operations: Rs 27,548 crore compared to Rs 25,455 crore during FY24, change 8.2%.
  • EBITDA: Rs 7,128 crore compared to Rs 6,233 crore during FY24, change 14.4%.
  • EBITDA margin: 25.9% for FY25.
  • PAT: Rs 5,273 crore compared to Rs 4,106 crore during FY24, change 28.4%.

Umang Vohra MD and Global CEO, Cipla, said: “I am pleased to share that we continue to make considerable progress across our focused markets. In FY25, we recorded a revenue growth of 8% over last year with the EBITDA margin of 25.9%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 7% YoY. Key therapies in Branded Prescription business continued to outpace the market growth, Trade Generics business growth trajectory is back on track and Anchor brands of Consumer Health Business maintained leadership position. With a positive traction in our differentiated assets, the US business posted an all-time high annual revenue of USD 934 million. In One Africa, we recorded a solid growth of 12% YoY in USD terms, powered by firm performance across key markets. Emerging Markets and Europe delivered a substantial revenue growth of 15% YoY on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front”.

Result PDF

Pharmaceuticals company Cipla announced Q3FY25 results

  • Income from Operations: Rs 7,073 crore, change 8% YoY.
  • EBITDA: Rs 1,989 crore, change 16% YoY.
  • EBITDA margin: 28.1% for Q3FY25.
  • PAT: Rs 1,571 crore, change 50% YoY.
  • PAT margin: 22.2% for Q3FY25.

Umang Vohra MD & Global CEO, Cipla, said: “I am pleased to share that we continue to make considerable progress across our focused markets. In Q3FY25, we delivered growth across all our various geographies, despite of a supply challenge in the U.S. We recorded a revenue growth of 8% over last year with a highest-ever EBITDA margin of 28.1%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 10% YoY. Key therapies in Branded Prescription business continued to outpace the market growth, Trade Generics business growth trajectory is back on track and Anchor brands of Consumer Health Business maintained leadership position. With a positive traction in our differentiated assets, the US business posted a revenue of USD 226 million. In South Africa, we recorded a solid growth of 21% YoY in local currency terms. Emerging Markets and Europe delivered a substantial revenue growth of 20% YoY on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front”.

Result PDF

Pharmaceuticals company Cipla  announced Q2FY25 results

Financial Highlights:

  • Highest-ever quarterly Revenue and EBITDA margin at 26.7%.
  • Income from Operations: Rs 7,051 crore, change 9% YoY.
  • EBITDA: Rs 1,886 crore, change 12% YoY.
  • EBITDA margin: 26.7%.
  • PAT: Rs 1,303 crore, change 17% YoY.
  • PAT Margin: 18.5%.

Business Highlights:

  • One India Business grew at 5% YoY. Branded Prescription business continued to outpace the market in key Chronic therapies. CHL delivered strong growth at 21% YoY. The business however, witnessed a historically slow seasonal growth in Acute category impacting both Branded Prescription and Trade Generics business.
  • Delivered quarterly revenue of USD 237 million up by 4% YoY supported by traction in differentiated portfolio.
  • Progressing on the journey of strengthening the Africa story, the North Africa business which was a part of Emerging markets and Europe is now merged with SAGA region which is renamed as One Africa. Momentum continues with overall revenue growth at 22%.
  • Emerging Markets and Europe: Posted a robust revenue growth of 18% in USD terms.
  • R&D investments: stand at INR 385 crore or 5.5% of sales, higher by 2% YoY driven by product filings and developmental efforts.
  • Net cash position of Rs 7,950 crore; Debt primarily includes lease liabilities and working capital requirements.

Umang Vohra MD and Global CEO, Cipla, said: “I am pleased to share that we continue to make considerable progress across our focused markets. In Q2FY25, we recorded a revenue growth of 9% over last year with a highest-ever EBITDA margin of 26.7%, driven by mix and other operational efficiencies. Our One-India business was impacted during the quarter due to changed seasonal pattern, however key chronic therapies in Branded Prescription business continued to grow faster than the market. Consumer health business grew at a strong 21% YoY. With our concentrated focus in differentiated portfolio, the US business posted a revenue of USD 237 million. In South Africa, we recorded a solid growth of 22% YoY in local currency terms, led by Private Market. Emerging Markets and Europe delivered a robust revenue growth of 18% YoY on the back of deep market focus strategy. Going ahead, focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front”.

Result PDF

Pharmaceuticals company Cipla announced Q1FY25 results:

Financial Highlights:

  • Income from Operations: Rs 6,694 crore, up by 7% YoY
  • EBITDA: Rs 1,716 crore, up by 14% YoY
  • PAT: Rs 1,178 crore, up by 17% YoY

Business Highlights:

  • One-India: India Branded Prescription Business grew at a healthy rate of 10% YoY. Overall One India growth was offset by softness in Trade Generics Business owing to distribution model change.
  • North America: All-time high revenue at USD 250 million up by 13% YoY supported by traction in differentiated portfolio.
  • South Africa: Momentum continues with revenue growth at 19% in local currency terms. Prescription business ranked #1 in the market
  • R&D investments: stand at Rs 353 crore or 5.3 % of sales, higher by 1% YoY driven by product filings and developmental efforts.
  • Strong net cash: Net cash position of Rs 8,449 crore; Debt primarily includes lease liabilities and working capital requirements.
  • Compliance update: Patalganga and Kurkumbh facilities were classified as ‘VAI’ by USFDA.

Umang Vohra MD and Global CEO, Cipla said: I am pleased to share that we continue to make considerable progress across our focused markets. In Q1FY25, we recorded revenue growth of 7% over last year with EBITDA margin of 25.6% driven by mix and other operational efficiencies. Our One-India business continued on its growth trajectory during the quarter, led by Branded Prescription which grew at 10%. Our concentrated focus and execution in differentiated portfolio have further strengthened the US business which yet again posted all-time high quarterly revenue at USD 250 million. In South Africa, we recorded a solid growth of 19% YoY in local currency terms, led by Private Market. Going ahead, focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front”.

Result PDF

Pharmaceuticals company Cipla announced Q4FY24 & FY24 results:

FY24 Financial Highlights:
For the fiscal year 2024, Cipla's annual revenue surpassed Rs 25,000 crore with a growth of 14% YoY, while the Profit After Tax (PAT) soared by an impressive 47% YoY to Rs 4,106 crore.

Q4FY24 Financial Highlights:

For Q4FY24, Cipla's revenue was Rs 6,163 crore with a growth of 10% YoY, while the Profit After Tax (PAT) soared by an impressive 79% YoY to Rs 939 crore.

Umang Vohra MD and Global CEO, Cipla, said “I am pleased to share our performance for the year where we made substantial progress across our focused markets. In FY24, our revenues crossed the threshold of Rs 25,000 crore whereas operating margins significantly improved to cross Rs 6,000 crore for very first time, growing at healthy 14% on topline and 26% on profitability YoY. This was backed by One-India revenue breaching Rs 10,000 crore, North America revenue surpassing USD 900 million and South Africa reaching top spot in prescription market, with all three businesses growing in double digits over last year with improved profitability. As we enter into FY25, our focus will be on our priorities of market leading growth in our key markets, growing big brands bigger, investing in future pipeline as well as focusing on resolutions on regulatory front”.

Result PDF

Pharmaceuticals firm Cipla announced Q3FY24 result:

Financial Highlights:

  • Income from Operations: Rs 6,544 crore, representing a 14.2% YoY increase.

  • EBITDA: Rs 1,720 crore, translating to 26.3% of Income from Operations, reflecting a 24.9% YoY growth.

  • Profit After Tax (PAT): Rs 1,049 crore, marking a substantial increase of 32.7% YoY.

Business Performance by Region:

  • One-India: Revenue growth stood at 12% YoY, bolstered by Branded Prescription, Trade Generics, and Consumer Health verticals. The market share for chronic therapy increased by 115 bps YoY to 60.3%.
  • North America: Recorded highest ever quarterly revenue at $230 Mn, an 18% YoY growth, driven by volume traction in key assets such as Lanreotide and Albuterol, along with strong base business demand.
  • South Africa: Demonstrated a 15% growth in local currency terms YoY, fueled by strong performance across prescription, OTC, and tender segments.

Research and Development (R&D):

  • Investment: R&D investments were reported at Rs 400 crore or 6.1% of sales, showcasing an increase of 10% YoY.

Balance Sheet Health:

  • Robust Net Cash Position: Rs 7,143 crore post the repayment of ZAR 720 Mn term loan in South Africa.

Umang Vohra, MD and Global CEO of Cipla Ltd, stated: "I am happy to announce results for yet another quarter which further established our strengths of our core business in India, North America, and South Africa. Our topline growth for the quarter was at an impressive 14% YoY with strong EBITDA margins at 26.3%. One India business grew at a healthy 12% YoY backed by strong performance across Branded Prescroreiption, Trade Generics and Consumer Health. In North America, we continue to scale newer peaks by posting the highest ever quarterly revenue yet again at $ 230 Mn, supported by positive traction in key assets and base business. Our South Africa business further extended its momentum from last quarter by growing at 15% in local currency terms driven by strong execution across prescription, OTC, and tender. Our focus continues on expansion in chronic therapies, growing big brands, global wellness as well as developing our R&D pipeline in respiratory and peptides. We will continue to focus on driving profitable growth across businesses".

 

 

Result PDF

Pharmaceuticals company Cipla announced Q2FY24 results:


1. Financial Performance:
- Cipla achieves highest ever quarterly revenue of Rs 6,678 crore, a 14.6% YoY increase.
- EBITDA margin reaches a record 26% at Rs 1,734 crore, a 33.1% YoY growth.
- PAT stands at Rs 1,131 crore, a significant 43.4% YoY increase.
- R&D investments increased by 13% YoY, totaling Rs 379 crore or 5.7% of sales.
- Strong balance sheet health continues with a robust net cash position of Rs 5,850 crore.

2. One-India Business:
- One-India business records a 10% YoY growth, driven by strong performance in Branded Prescription and Trade Generics.
- Branded Prescription grows at 11% YoY, outperforming the market.
- Trade Generics achieve double-digit growth despite weak seasonality, aided by declining raw material costs.
- Consumer Health sees improvement, with chronic share increasing by 140 bps YoY to 60%.

3. North America:
- North America business reaches a quarterly revenue of USD 229 million, growing by 28% YoY.
- Market share expands across key differentiated assets, with Lanreotide's market share at 20%.
- Strong traction and share expansion in core products drive the growth in North America.

4. South Africa:
- The private Market in South Africa grows at 12% YoY in local currency terms, outpacing the overall market.
- Robust performance in prescription and OTC contributes to the growth.
- Acquisition of Actor expected to expand OTC share.

Umang Vohra, MD and Global CEO, Cipla said, "Pleased to share an exceptional set of results reflecting the strength of our core business across key markets of India, North America, and South Africa. We reported our highest-ever quarterly revenue with EBITDA margins scaling up to 26%. One-India business grew at a healthy 10% YoY with continued market-beating performance in the branded prescription and Trade Generics business. In South Africa, the private market business grew in double digits driven by strong execution across prescription and OTC. The North America business scaled up to USD 229 million, growing 28% YoY, driven by strong traction across core products with share expansion in differentiated assets. Our pipeline is progressing well with key milestones achieved in Respiratory and Peptide assets. We will continue our focus on driving profitable growth across businesses"

 

 

Result PDF

Pharmaceuticals company Cipla announced Q1FY24 results:

  • Income from operations of Rs 6,329 crore, up 17.7% YoY
  • EBITDA of Rs 1,494 crore, up 30.7% YoY
  • PAT of Rs 996 crore, up 45.1% YoY
  • One-India: Robust growth across branded prescription, trade generics, and consumer health over the last year, resulting in growth in our One-India Franchise by 12% YoY. 
  • US business: Reported highest-ever revenue of USD 222 million and 43% YoY growth driven by robust momentum in a  differentiated portfolio.
  • South Africa: South Africa's Private Market business grew at 13% YoY in local currency terms backed by double-digit growth in both prescription and OTC business. In the private market, our business now ranks # 2 in terms of market share. 
  • R&D investments stand at Rs 349 crore or 5.5 % of sales; Higher by 27% YoY driven by the continued progress of clinical trials on key pipeline assets and other developmental efforts. 

“I am pleased to share that we continue to make considerable progress across our focused markets. In Q1FY24, we recorded growth of 18% over last year with EBITDA of Rs 1,494 crore driven by mix and other operational efficiencies. Our One-India business continued the double-digit trajectory growing at 12% during the quarter led by branded prescription with sustained growth across chronic therapies. Our continued focus on a differentiated portfolio has strengthened our US business which once again posted the highest ever quarterly revenue at USD 222 million. South Africa Private Market bounced back from the lows of last year to post double-digit growth. Our core operating profitability continues to be strong at 23.6% expanding by 230 bps over last year. We are excited to continue working towards establishing a strong foundation for growth in upcoming quarters, where we look forward to continuing the leadership in Chronic Therapies in Branded Prescription business in India, further expanding our differentiated pipeline in the US and targeting to be the biggest prescription business in South Africa.” said Umang Vohra,  MD and Global CEO, Cipla.

 

  

Result PDF

Trending News

Saregama India's announced strategic partnership with, and investment in, Sanjay Leela Bhansali's Bhansali Productions

Saregama India's announced strategic partnership with, and investment in, Sanjay Leela Bhansali's Bhansali Productions

Published on 17-Dec-2025 09:01

The Competition Commission of India (CCI) has approved ITC’s acquisition of the paper and pulp manufacturing business of Aditya Birla Real Estate Ltd (ABREL).

The Competition Commission of India (CCI) has approved ITC’s acquisition of the paper and pulp manufacturing business of Aditya Birla Real Estate Ltd (ABREL)

Published on 17-Dec-2025 09:00

Zydus Lifesciences has received a USFDA acceptance for its ANDA of for copper histidinate (CUTX-101), intended to treat Menkes disease in pediatric patients.

Zydus Lifesciences has received a USFDA acceptance for its ANDA of for copper histidinate (CUTX-101), intended to treat Menkes disease in pediatric patients.

Published on 16-Dec-2025 09:05

KIMS has commenced operations at its newly established hospital located at the PES University campus in Electronic City, Bengaluru

Krishna Institute of Medical Sciences (KIMS) has commenced operations at its newly established hospital located at the PES University campus in Electronic City, Bengaluru

Published on 16-Dec-2025 09:03

Power Grid Corporation of India Ltd (POWERGRID) has been declared the successful bidder under Tariff-Based Competitive Bidding

Power Grid Corporation of India Ltd (POWERGRID) has been declared the successful bidder under Tariff-Based Competitive Bidding 

Published on 16-Dec-2025 09:01

Marico is in talks to acquire Cosmix, a startup that sells plant-based protein supplements

Marico is in talks to acquire Cosmix, a startup that sells plant-based protein supplements

Published on 16-Dec-2025 09:00

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status